Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756258 | 0.83 | ELANE (0.36) | KDM4EALDH1A1HPGDPARP1NPC1 | |
| SCHEMBL12328106 | 0.82 | HSD17B10 (0.44) | KDM4EHSD17B10LMNAADORA3ADORA2A | |
| SCHEMBL12328110 | 0.82 | TYMS (0.43) | KDM4EHSD17B10LMNAADORA3ADORA2A | |
| SCHEMBL6542923 | 0.81 | ADORA3 (0.43) | LMNAADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL12309239 | 0.80 | KDM4E (0.45) | KDM4EHSD17B10LMNAADORA3ADORA2A | |
| SCHEMBL22962291 | 0.80 | KDM4E (0.45) | KDM4EHSD17B10LMNAADORA3ADORA2A | |
| SCHEMBL22962172 | 0.80 | KDM4E (0.45) | KDM4EHSD17B10LMNAADORA3ADORA2A | |
| SCHEMBL15042816 | 0.80 | KDM4E (0.50) | KDM4EHSD17B10LMNAADORA3ADORA2A | |
| SCHEMBL24122963 | 0.78 | NSD2 (0.34) | LMNAALDH1A1HPGDPARP1NPC1 | |
| SCHEMBL6757192 | 0.78 | KDM4E (0.42) | KDM4EHSD17B10LMNAADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0428260-B1 | Metal surface treatment agents | SANWA LAB LTD (JP) | 2000-01-05 | — | — | EP | claimed |
| EP-0562187-B1 | Process for production of copper through-hole printed wiring boards | SANWA LAB LTD (JP) | 1996-01-10 | — | — | EP | claimed |
| US-5275694-A | Printed circuits with copper through holes, negative patterns, photoresists, lamination, dipping and etching | SANWA LABORATORY LTD. (JP) | 1994-01-04 | — | — | US | claimed |
| EP-0562187-A1 | Process for production of copper through-hole printed wiring boards | SANWA LABORATORY LTD. (JP) | 1993-09-29 | — | — | EP | claimed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | claimed |
| EP-3752498-B1 | SOMATOSTATIN MODULATORS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-3675858-B1 | IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | OPTIKIRA LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11072598-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210040087-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-11 | — | — | US | disclosed |
| US-10189830-B2 | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| US-8183276-B2 | Therapeutic agents | MERCK SHARP & DOHME CORP. | 2012-05-22 | — | — | US | disclosed |
| US-20100324029-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME CORP. | 2010-12-23 | — | — | US | disclosed |
| WO-1998037072-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-08-27 | — | — | WO | disclosed |
| EP-0562187-B1 | Process for production of copper through-hole printed wiring boards | SANWA LAB LTD (JP) | 1996-01-10 | — | — | EP | disclosed |
| US-5275694-A | Printed circuits with copper through holes, negative patterns, photoresists, lamination, dipping and etching | SANWA LABORATORY LTD. (JP) | 1994-01-04 | — | — | US | disclosed |
| EP-0562187-A1 | Process for production of copper through-hole printed wiring boards | SANWA LABORATORY LTD. (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0186190-B1 | BENZIMIDAZOLE DERIVATIVES, AND THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-05-26 | — | — | EP | disclosed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | disclosed |
| US-4663339-A | Acaricidal and insecticidal substituted 1-phenylalkylbenzimidazoles | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-05-05 | — | — | US | disclosed |
| EP-0186190-A2 | Benzimidazole derivatives, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040087-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | KDM4E 4554/4885HSD17B10 3787/4885LMNA 3475/4885 |
| US-20100324029-A1 | THERAPEUTIC AGENTS | PSEN2, PSEN1, BACE2 | KDM4E 3970/4885HSD17B10 1886/4885LMNA 1357/4885 |
| US-10189830-B2 | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders | NQO1, COQ8A, NDUFAB1 | KDM4E 2885/4885HSD17B10 320/4885LMNA 1969/4885 |
| US-11072598-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | KDM4E 4554/4885HSD17B10 3787/4885LMNA 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.